MPLT vs ACNB vs PTGX

For growth investors, ACNB Corporation (ACNB) is the stronger pick with 28.

9% revenue growth year-over-year, versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). ACNB Corporation (ACNB) offers the better valuation at 14. 6x trailing P/E (9. 6x forward), making it the more compelling value choice. Analysts rate ACNB Corporation (ACNB) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, ACNB Corporation is actually cheaper at 9.

6x.

Over the past 5 years, Protagonist Therapeutics, Inc.

(PTGX) delivered a total return of +246. 4%, compared to +62. 6% for MapLight Therapeutics, Inc. (MPLT). Over 10 years, the gap is even starker: PTGX returned +773. 3% versus MPLT's +59. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Protagonist Therapeutics, Inc.

(PTGX) is the lower-risk stock at 0. 20β versus ACNB Corporation's 0. 69β — meaning ACNB is approximately 246% more volatile than PTGX relative to the S&P 500. On balance sheet safety, Protagonist Therapeutics, Inc. (PTGX) carries a lower debt/equity ratio of 2% versus 78% for ACNB Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ACNB Corporation (ACNB) is pulling ahead at 28.

9% versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). On earnings-per-share growth, the picture is similar: ACNB Corporation grew EPS -3. 5% year-over-year, compared to -148. 5% for Protagonist Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACNB Corporation (ACNB) is the more profitable company, earning 21.

7% net margin versus -282. 8% for Protagonist Therapeutics, Inc. — meaning it keeps 21. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACNB leads at 27. 3% versus -343. 6% for PTGX. At the gross margin level — before operating expenses — PTGX leads at 97. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, ACNB Corporation (ACNB) trades at 9.

6x forward P/E versus 25. 7x for Protagonist Therapeutics, Inc. — 16. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MPLT: 15. 4% to $33. 80.

In this comparison, ACNB (2.

7% yield) pays a dividend. MPLT, PTGX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Protagonist Therapeutics, Inc.

(PTGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 20), +773. 3% 10Y return). Both have compounded well over 10 years (PTGX: +773. 3%, MPLT: +59. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MPLT (Healthcare) and ACNB (Financial Services) and PTGX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MPLT is a small-cap quality compounder stock; ACNB is a small-cap high-growth stock; PTGX is a small-cap quality compounder stock. ACNB pays a dividend while MPLT, PTGX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.